SN-117M LABELED MANNOSE COUPLED DEXTRAN AMINE
Amine modified dextran is labeled with mannose molecules as well as tin-117m. This tin-117m labeled mannose modified dextran is useful in treating maladies that express CD206, in particular rheumatoid arthritis, as well as the cancer typically located in the lymph nodes. This provides a systemic treatment for such maladies. The tin-117m will destroy cells to which it is bonded and also can be imaged. Further, due to the nature of the radiation from the tin-117m, it does not do significant damage to nearby healthy cells.
1 . A method of treating or imaging a malady which expresses CD206 by injecting into a mammal with said malady, a dosage of tin-117m labeled mannose modified dextran, said dosage effective to treat or image said malady.
2 . The method claimed in claim 1 wherein said tin-117m is no-carrier-added high specific activity tin-117m.
3 . The method claimed in claim 2 wherein said malady is rheumatoid arthritis.
4 . The method claimed in claim 1 wherein said malady is cancer.
5 . The method claimed in claim 1 wherein said effective dosage is from 0.05 mCi to 40 mCi.
6 . The method claimed in claim 1 wherein said effective dosage is a hormetic dosage.
7 . A method inducing cellular apoptosis in rheumatologic conditions by administering to a mammal a hormetic dosage of no-carrier-added high specific activity tin-117m labeled mannose modified dextran.
8 . A method of inducing cellular apoptosis in cancer cells in a mammal by administering to said mammal a hormetic dosage of no-carrier-added high specific activity tin-117m labeled mannose modified dextran.
9 . A compound comprising:
a dextran chain having a plurality of mannose molecules bound to said chain and further having a plurality of tin-117m atoms bound to said dextran chain.
10 . The compound of claim 9 wherein said dextran has a molecular weight of 10 to 30 kDa.
11 . The compound claimed in claim 9 wherein a plurality of charged molecules are bonded to said dextran chain.
12 . The compound claimed in claim 9 wherein said plurality of mannose molecules are attached to said dextran chain by amine leashes.
13 . The compound claimed in claim 9 wherein said tin-117m is bonded to aminobenzyl-DOTA which is attached to said dextran chain by amine leashes.
14 . The compound claimed in claim 13 wherein said tin-117m is no-carrier-added, high specific activity tin-117m.
15 . The compound claimed in claim 9 further comprising hydrophilic groups attached to said dextran chain.
16 . The compound claimed in claim 15 wherein said hydrophilic groups are DPTA or the dianhydride of DTPA.